Advanced Cancer Clinical Trial
— EMPallAOfficial title:
Emergency Medicine Palliative Care Access (EMPallA)
Verified date | May 2024 |
Source | NYU Langone Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a two-arm, multi-site randomized controlled trial of 1,350 older adults (50+ years) with either advanced cancer (defined as metastatic solid tumor) or poor prognosis end-stage organ failure (New York Heart Association (NYHA) Class III or IV Congestive Heart Failure (CHF), End-Stage Renal Disease (ESRD), defined as Glomerular Filtration Rate (GFR) < 15 ml/min/m2 or dialysis ; or Global Initiative for Chronic Obstructive Lung Disease (GOLD) Stage III or higher, or oxygen-dependent chronic obstructive pulmonary disease (COPD) who present to the Emergency Department (ED), along with 675 of their informal caregivers. Investigators will compare the effectiveness of two distinct palliative care models: a) nurse-led telephonic case management; and b) facilitated, outpatient specialty palliative care.
Status | Completed |
Enrollment | 1350 |
Est. completion date | August 24, 2023 |
Est. primary completion date | August 24, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: Patients: - English or Spanish-speaking patients ages 50 years and older - Qualifying serious, life-limiting conditions and who are scheduled for ED discharge, observation status, or admission for two midnights or less. - Qualifying conditions include: advanced cancer (defined as metastatic solid tumor) or poor prognosis end-stage organ failure New York Heart Association (NYHA) Class III or IV Congestive Heart Failure (CHF), End-Stage Renal Disease (ESRD), defined as Glomerular Filtration Rate (GFR) < 15 ml/min/m2 or dialysis; or Global Initiative for Chronic Obstructive Lung Disease (GOLD) Stage III or higher or stage III or IV, or oxygen-dependent chronic obstructive pulmonary disease (COPD) defined as Global Initiative for Chronic Obstructive Lung Disease (GOLD) - Patients must have health insurance, reside within the geographical area, and have a working telephone. Informal Caregivers: - English or Spanish-speaking primary caregivers (relative or friend who has contact with the patient at least two times per week) ages 18 years and older. Exclusion Criteria: - Patients with dementia identified in the EHR, who received hospice services in the last six months, who have received 2 or more palliative care visits in the last 6 months, and those who reside in a skilled nursing or assisted living facility, or chronic care hospital. |
Country | Name | City | State |
---|---|---|---|
United States | Brigham and Women's Hospital/Dana-Farber Cancer Institute | Boston | Massachusetts |
United States | NYU Langone Hospital- Brooklyn | Brooklyn | New York |
United States | Northwestern Memorial Hospital | Chicago | Illinois |
United States | Rush University Medical Center | Chicago | Illinois |
United States | Ohio State University (OSU) | Columbus | Ohio |
United States | Henry Ford Health System | Detroit | Michigan |
United States | University of Florida (UF) | Gainesville | Florida |
United States | Hackensack University Medical Center | Hackensack | New Jersey |
United States | University of California, Los Angeles Ronald Reagan Medical Center | Los Angeles | California |
United States | NYU Langone Health Hospital Long Island | Mineola | New York |
United States | Atlantic Health System, Morristown Medical Center | Morristown | New Jersey |
United States | Yale University | New Haven | Connecticut |
United States | Bellevue Hospital | New York | New York |
United States | New York University Langone Tisch Hospital | New York | New York |
United States | University of California Irvine Medical Center | Orange | California |
United States | Beaumont Health | Royal Oak | Michigan |
United States | University of California San Diego Medical Center | San Diego | California |
United States | William Beaumont Hospital, Troy | Troy | Michigan |
Lead Sponsor | Collaborator |
---|---|
NYU Langone Health | Atlantic Health, Beaumont Health, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Hackensack Meridian Health, Henry Ford Health System, Northwestern University, Ohio State University (OSU), Patient-Centered Outcomes Research Institute, Rush University, University of California Irvine (UCI), University of California Los Angeles (UCLA), University of California San Diego (UCSD), University of Florida (UF), Yale University |
United States,
Booker-Vaughns J, Rosini D, Batra R, Chan GK, Dunn P, Galvin R, Hopkins E 3rd, Isaacs E, Kizzie-Gillett CL, Maguire M, Navarro M, Reddy Pidatala N, Vaughan W, Welsh S, Williams P, Young-Brinn A, Van Allen K, Cuthel AM, Liddicoat Yamarik R, Flannery M, Goldfeld KS, Grudzen CR. What's in This For You? What's in This For Me?: A Win-Win Perspective of Involving Study Advisory Committee Members in Palliative Care Research. J Patient Exp. 2024 Jan 2;11:23743735231224562. doi: 10.1177/23743735231224562. eCollection 2024. — View Citation
Brickey J, Flannery M, Cuthel A, Cho J, Grudzen CR; EMPallA Investigators. Barriers to recruitment into emergency department-initiated palliative care: a sub-study of a multi-site, randomized controlled trial. BMC Palliat Care. 2022 Feb 15;21(1):22. doi: 10.1186/s12904-021-00899-9. — View Citation
de Forcrand C, Flannery M, Cho J, Reddy Pidatala N, Batra R, Booker-Vaughns J, Chan GK, Dunn P, Galvin R, Hopkins E, Isaacs ED, Kizzie-Gillett CL, Maguire M, Navarro M, Rosini D, Vaughan W, Welsh S, Williams P, Young-Brinn A, Grudzen CR. Pragmatic Considerations in Incorporating Stakeholder Engagement Into a Palliative Care Transitions Study. Med Care. 2021 Aug 1;59(Suppl 4):S370-S378. doi: 10.1097/MLR.0000000000001583. — View Citation
Grudzen CR, Schmucker AM, Shim DJ, Ibikunle A, Cho J, Chung FR, Cohen SE; EMPallA Outpatient Investigators. Development of an Outpatient Palliative Care Protocol to Monitor Fidelity in the Emergency Medicine Palliative Care Access Trial. J Palliat Med. 2019 Sep;22(S1):66-71. doi: 10.1089/jpm.2019.0115. — View Citation
Grudzen CR, Shim DJ, Schmucker AM, Cho J, Goldfeld KS; EMPallA Investigators. Emergency Medicine Palliative Care Access (EMPallA): protocol for a multicentre randomised controlled trial comparing the effectiveness of specialty outpatient versus nurse-led telephonic palliative care of older adults with advanced illness. BMJ Open. 2019 Jan 25;9(1):e025692. doi: 10.1136/bmjopen-2018-025692. — View Citation
Liddicoat Yamarik R, Chiu LA, Flannery M, Van Allen K, Adeyemi O, Cuthel AM, Brody AA, Goldfeld KS, Schrag D, Grudzen CR, On Behalf Of The EMPallA Investigators. Engagement, Advance Care Planning, and Hospice Use in a Telephonic Nurse-Led Palliative Care Program for Persons Living with Advanced Cancer. Cancers (Basel). 2023 Apr 15;15(8):2310. doi: 10.3390/cancers15082310. — View Citation
Schmucker AM, Flannery M, Cho J, Goldfeld KS, Grudzen C; EMPallA Investigators. Data from emergency medicine palliative care access (EMPallA): a randomized controlled trial comparing the effectiveness of specialty outpatient versus telephonic palliative care of older adults with advanced illness presenting to the emergency department. BMC Emerg Med. 2021 Jul 12;21(1):83. doi: 10.1186/s12873-021-00478-4. — View Citation
Tan AJ, Yamarik R, Brody AA, Chung FR, Grudzen C; EMPallA Telephonic Working Group. Development and protocol for a nurse-led telephonic palliative care program. Nurs Outlook. 2021 Jul-Aug;69(4):626-631. doi: 10.1016/j.outlook.2020.12.011. Epub 2021 Jan 21. — View Citation
Yamarik RL, Tan A, Brody AA, Curtis J, Chiu L, Bouillon-Minois JB, Grudzen CR. Nurse-Led Telephonic Palliative Care: A Case-Based Series of a Novel Model of Palliative Care Delivery. J Hosp Palliat Nurs. 2022 Apr 1;24(2):E3-E9. doi: 10.1097/NJH.0000000000000850. — View Citation
Yusufov M, Adeyemi O, Flannery M, Bouillon-Minois JB, Van Allen K, Cuthel AM, Goldfeld KS, Ouchi K, Grudzen CR. Psychometric Properties of the Functional Assessment of Cancer Therapy-General for Evaluating Quality of Life in Patients With Life-Limiting Illness in the Emergency Department. J Palliat Med. 2024 Jan;27(1):63-74. doi: 10.1089/jpm.2022.0270. Epub 2023 Sep 6. — View Citation
Zhao N, Cuthel AM, Storms O, Zhang R, Yamarik RL, Hill J, Kaur R, Van Allen K, Flannery M, Chang A, Chung F, Randhawa S, Alvarez IC, Young-Brinn A, Kizzie-Gillett CL, Rosini D, Isaacs ED, Hopkins E 3rd, Chan GK, Booker-Vaughns J, Maguire M, Navarro M, Pidatala NR, Dunn P, Williams P, Galvin R, Batra R, Welsh S, Vaughan W, Bouillon-Minois JB, Grudzen CR. Advancing patient-centered research practices in a pragmatic patient-level randomized clinical trial: A thematic analysis of stakeholder engagement in Emergency Medicine Palliative Care Access (EMPallA). Res Involv Engagem. 2024 Jan 23;10(1):10. doi: 10.1186/s40900-023-00539-x. — View Citation
* Note: There are 11 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in quality of life for patients, as measured by the Functional Assessment of Cancer Therapy - General (FACT-G) | Measured by change from enrollment to 6 months
Used to measure a person's quality of life 27 questions total 5-point Likert scale Reverse code select items per scoring guidelines at facit.org, then calculate a summary score for each respondent. The total score ranges from 0-108 points; higher scores indicate greater quality of life. |
Baseline, Month 6 | |
Secondary | Patient Level: Healthcare Utilization, as measured by number of ED revisits | -Measured from enrollment to 12 months | Up to Month 12 | |
Secondary | Patient Level: Healthcare Utilization, as measured by number of Inpatient Days | -Measured from enrollment to 12 months | Up to Month 12 | |
Secondary | Patient Level: Healthcare Utilization, as measured by number of patients with Hospice use | -Measured from enrollment to 12 months | Up to Month 12 | |
Secondary | Loneliness, as measured by the Three-Item Loneliness Scale | Used to measure how often a person feels disconnected from others
Three questions total 3-point rating scale (1 = Hardly ever, 2 = Some of the time, 3 = Often) Total score is the sum of responses and ranges from 3 to 9; higher scores indicate greater loneliness. measured by change from enrollment to 3 months |
Baseline, Month 3 | |
Secondary | Loneliness, as measured by the Three-Item Loneliness Scale | Used to measure how often a person feels disconnected from others
Three questions total 3-point rating scale (1 = Hardly ever, 2 = Some of the time, 3 = Often) Total score is the sum of responses and ranges from 3 to 9; higher scores indicate greater loneliness. measured by change from enrollment to 6 months |
Baseline, Month 6 | |
Secondary | Loneliness, as measured by the Three-Item Loneliness Scale | Used to measure how often a person feels disconnected from others
Three questions total 3-point rating scale (1 = Hardly ever, 2 = Some of the time, 3 = Often) Total score is the sum of responses and ranges from 3 to 9; higher scores indicate greater loneliness. measured by change from enrollment to 12 months |
Baseline, Month 12 | |
Secondary | Symptom burden, as measured by Edmonton Symptom Assessment Scale Revised (ESAS-r) | Used to measure severity of symptoms
10 questions Each item is rated on a 0-10 scale (0= none to 10 worst possible) Total score ranges from 0 to 100; higher scores indicate greater severity of symptoms. measured by change from enrollment to 3 months |
Baseline, Month 3 | |
Secondary | Symptom burden, as measured by Edmonton Symptom Assessment Scale Revised (ESAS-r) | Used to measure severity of symptoms
10 questions Each item is rated on a 0-10 scale (0= none to 10 worst possible) Total score ranges from 0 to 100; higher scores indicate greater severity of symptoms. measured by change from enrollment to 6 months |
Baseline, Month 6 | |
Secondary | Symptom burden, as measured by Edmonton Symptom Assessment Scale Revised (ESAS-r) | Used to measure severity of symptoms
10 questions Each item is rated on a 0-10 scale (0= none to 10 worst possible) Total score ranges from 0 to 100; higher scores indicate greater severity of symptoms. measured by change from enrollment to 12 months |
Baseline, Month 12 | |
Secondary | Change in Caregiver Quality of Life, as measured by the Patient-Reported Outcome Measurement Information System (PROMIS-10) | Quality of life for informal caregivers will be measured using the 10-item Patient-Reported Outcome Measurement Information System (PROMIS-10), an instrument designed to measure perceptions of health using global health items.
Scored by reverse coding with a raw score ranging from 0-20; 0 points represent the patient's most severe physical and/or mental impairment, while 20 points represent the best possible state of health. measured by change from enrollment to 3 months |
Baseline, Month 3 | |
Secondary | Change in Caregiver Quality of Life, as measured by the Patient-Reported Outcome Measurement Information System (PROMIS-10) | Quality of life for informal caregivers will be measured using the 10-item Patient-Reported Outcome Measurement Information System (PROMIS-10), an instrument designed to measure perceptions of health using global health items.
Scored by reverse coding with a raw score ranging from 0-20; 0 points represent the patient's most severe physical and/or mental impairment, while 20 points represent the best possible state of health. measured by change from enrollment to 6 months |
Baseline, Month 6 | |
Secondary | Change in Caregiver Quality of Life, as measured by the Patient-Reported Outcome Measurement Information System (PROMIS-10) | Quality of life for informal caregivers will be measured using the 10-item Patient-Reported Outcome Measurement Information System (PROMIS-10), an instrument designed to measure perceptions of health using global health items.
Scored by reverse coding with a raw score ranging from 0-20; 0 points represent the patient's most severe physical and/or mental impairment, while 20 points represent the best possible state of health. measured by change from enrollment to 12 months |
Baseline, Month 12 | |
Secondary | Caregiver Bereavement, as measured by the Texas Inventory of Grief | Measured at 3 months post-patient death
Used to measure a caregiver's bereavement 19 items; each rated on a 5-point scale from 0 (never) to 4 (always) Total score is the sum of responses and ranges from 0 to 76; higher scores indicate greater levels of grief |
3 Months Post-Patient Death | |
Secondary | Change in Caregiver strain, as measured by the Zarit Burden Interview (ZBI-12) | Measured as change from enrollment to Month 3
Used to measure a caregiver's strain 12 items; each rated on a 3-point scale from 0 (yes, on a regular basis) to 3 (no) Total score is the sum of responses and ranges from 0 to 48; higher scores indicate greater burden |
Baseline, Month 3 | |
Secondary | Change in Caregiver strain, as measured by the Zarit Burden Interview (ZBI-12) | Measured as change from enrollment to Month 6
Used to measure a caregiver's strain 12 items; each rated on a 3-point scale from 0 (yes, on a regular basis) to 3 (no) Total score is the sum of responses and ranges from 0 to 48; higher scores indicate greater burden |
Baseline, Month 6 | |
Secondary | Change in Caregiver strain, as measured by the Zarit Burden Interview (ZBI-12) | Measured as change from enrollment to Month 12
Used to measure a caregiver's strain 12 items; each rated on a 3-point scale from 0 (yes, on a regular basis) to 3 (no) Total score is the sum of responses and ranges from 0 to 48; higher scores indicate greater burden |
Baseline, Month 12 | |
Secondary | Change in quality of life for patients, as measured by the FACT-G | Measured by change from enrollment to 3 months
Used to measure a person's quality of life 27 questions total 5-point Likert scale Reverse code select items per scoring guidelines at facit.org, then calculate a summary score for each respondent. The total score ranges from 0-108 points; higher scores indicate greater quality of life. |
Baseline, Month 3 | |
Secondary | Change in quality of life for patients, as measured by the FACT-G | Measured by change from enrollment to 12 months
Used to measure a person's quality of life 27 questions total 5-point Likert scale Reverse code select items per scoring guidelines at facit.org, then calculate a summary score for each respondent. The total score ranges from 0-108 points; higher scores indicate greater quality of life. |
Baseline, Month 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Completed |
NCT01901237 -
Yoga for Adolescent and Young Adult Non-Curative Cancer Patients
|
N/A | |
Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 |